Building a tool to predict spread of newly diagnosed breast cancer
Uses past medical records to estimate distant spread in women newly diagnosed with breast cancer.
Plain-language title generated from the registry record
Registry title: Diagnostic Prediction Model for De Novo Metastatic Breast Cancer
Key facts
- Where
- Szombathely, HungarySee the site
Where in Hungary
- Markusovszky University Teaching HospitalSzombathely, HungaryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Markusovszky University Teaching Hospital os County Vas
- Trial code
- NCT07752238
- Record updated
- 12 August 2026
- Original description
The goal of this observational study is to create a tool to estimate the risk of macroscopic distant tumor spread in women with newly diagnosed breast cancer. The main question it aims to answer is:Read full original descriptionShow less
Development of a Diagnostic Prediction Model for de Novo Metastatic Breast Cancer Using Routinely Available Baseline Parameters
The goal of this observational study is to create a tool to estimate the risk of macroscopic distant tumor spread in women with newly diagnosed breast cancer. The main question it aims to answer is:
• Can a model, which combines routine medical information collected at diagnosis, accurately predict if a patient has metastasis large enough to be found during systemic imaging? Researchers will review the past medical records of participants who were treated at a university hospital. Because this study looks at past data, participants will not be asked to do any new tasks, take new tests, or change their medical care.
Inclusion: Female sex, aged 18 years or older; Newly diagnosed invasive breast cancer; Case reviewed by the Multidisciplinary Tumour Board at the study site during the inclusion period (between October 1, 2018, and July 31, 2025); No history of prior or synchronous invasive malignancies, except for synchronous bilateral breast cancer; Intent for primary treatment and clinical management at the study site; Availability of longitudinal clinical records throughout the 12-month follow-up period or until death.
Exclusion: -Absence of baseline systemic staging.